Home › Multiple Myeloma › Colorado
Multiple Myeloma clinical trials in Colorado
37 studies for Multiple Myeloma are looking for participants at sites in Colorado.
Cities in Colorado
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07589634A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Local Institution - 0381, Aurora
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT05519085A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- Colorado Blood Cancer Institute /ID# 280275, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07409246A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Denver
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07391657A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05652335A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07518186A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06500884A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07073547A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06768489A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07258511A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Colorado Blood Cancer Institute /ID# 279080, Denver
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07095452Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- CBCI, Colorado Blood Cancer Institute, Denver
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07648264A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
- Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04910568Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06297226A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT07637578A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Denver
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT07681596MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- UCHealth Poudre Valley Hospital, Fort Collins
- UCHealth Harmony, Fort Collins
- UCHealth Greeley Hospital, Greeley
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Penrose-Saint Francis Healthcare, Colorado Springs
- Rocky Mountain Cancer Centers-Penrose, Colorado Springs
- Saint Francis Cancer Center, Colorado Springs
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04566328A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Colorado Blood Cancer Institute/SCRI, Denver
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06292780AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Aurora
- Research Site, Denver
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Aurora
- Research Site, Denver
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT07764978A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- Colorado Blood Cancer Institute /ID# 273129, Denver
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 21, 2026 · NCT06892522Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT05469893A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Rocky Mountain Cancer Centers - Aurora /ID# 268574, Aurora
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT05650632Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- UCHealth Poudre Valley Hospital, Fort Collins
- UCHealth Harmony, Fort Collins
- UCHealth Greeley Hospital, Greeley
- and 3 more
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT06057402Integrated Cancer Repository for Cancer Research
- Advent Health, Greenwood Village
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Rocky Mountain Regional VA Medical Center, Aurora
- Penrose-Saint Francis Healthcare, Colorado Springs
- Rocky Mountain Cancer Centers-Penrose, Colorado Springs
- and 6 more
RecruitingPhase 3
All ages · All sexes · Updated Jun 10, 2026 · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- University of Colorado Hospital, Aurora
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT05243797Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 2
Ages 19 and older · All sexes · Updated Jun 4, 2026 · NCT06974786A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- Colorado Blood Cancer Institute/SCRI, Denver
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 13, 2026 · NCT05828511Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Colorado Blood Cancer Institute /ID# 273751, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 12, 2026 · NCT06896916A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Aurora
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT06679101Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT05972135Survivors Uniting for Remote Guided Exercise
- Human Performance Clinical Research Lab, Fort Collins
Recruiting
Ages 18 and older · All sexes · Updated Mar 31, 2026 · NCT07290309A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Mar 24, 2026 · NCT04988555A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Colorado Blood Cancer Institute, Denver
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 18, 2026 · NCT06153251CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- CU Anschutz Medical Campus, Anshutz Cancer Pavillion, Aurora
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2025 · NCT05722418From ClinicalTrials.gov, data retrieved Oct 3, 2026. Each study sets its own eligibility; the study team decides who can join.